We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

56 hedge funds and large institutions have $12.1M invested in Oramed Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

162% more call options, than puts

Call options by funds: $136K | Put options by funds: $52K

101% more capital invested

Capital invested by funds: $5.99M → $12.1M (+$6.07M)

55% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 11

7.25% more ownership

Funds ownership: 5.7% → 12.95% (+7.2%)

0% more funds holding

Funds holding: 56 → 56 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

Holders
56
Holders Change
–
Holders Change %
0%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
17
Reduced
11
Closed
9
Calls
$136K
Puts
$52K
Net Calls
+$84K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
M
Murchinson
Ontario, Canada
+$2.24M
2
BFM
Boothbay Fund Management
New York
+$1.12M
3
BCM
BML Capital Management
Indiana
+$1.03M
4
Renaissance Technologies
Renaissance Technologies
New York
+$634K
5
Bank of America
Bank of America
North Carolina
+$536K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$401K
2
GCP
GSA Capital Partners
United Kingdom
-$232K
3
Citigroup
Citigroup
New York
-$108K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$71.2K
5
VF
Virtu Financial
New York
-$45K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
51
Federated Hermes
Pennsylvania
$852 +$528 +247 +202%
TSWM
52
Tyler-Stone Wealth Management
Ohio
$693 – – –
BCMLT
53
Beacon Capital Management LLC (Tennessee)
Tennessee
$572 – – –
GRP
54
Global Retirement Partners
California
$228 +$214 +100 New
BBHC
55
Brown Brothers Harriman & Co
New York
$18 – – –
BNP Paribas Financial Markets
56
BNP Paribas Financial Markets
France
$5 -$23 -11 -85%
Goldman Sachs
57
Goldman Sachs
New York
– -$401K -153,618 Closed
GCP
58
GSA Capital Partners
United Kingdom
– -$232K -88,923 Closed
Citigroup
59
Citigroup
New York
– -$108K -41,471 Closed
Dimensional Fund Advisors
60
Dimensional Fund Advisors
Texas
– -$71.2K -27,285 Closed
VF
61
Virtu Financial
New York
– -$45K -17,388 Closed
Prudential Financial
62
Prudential Financial
New Jersey
– -$29.2K -11,200 Closed
Invesco
63
Invesco
Georgia
– -$26.3K -10,094 Closed
Simplex Trading
64
Simplex Trading
Illinois
– -$5.33K -2,496 Closed
TWC
65
TD Waterhouse Canada
Ontario, Canada
– -$2.55K -1,000 Closed
1 2
3

ORMP Hedge Fund Activity: Q4 2023 in Review

56 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q4 2023, worth a combined $12.1M — up 101% from $5.99M a quarter earlier.

Fund positioning in ORMP was balanced in Q4 2023: 9 funds opened new positions, 9 closed out, 17 added to existing stakes and 11 trimmed.

The largest buyer was Murchinson, opening a new position worth an estimated $2.24M. The largest seller was Goldman Sachs, exiting entirely with an estimated $401K sold.

  • 56 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $12.1M of Oramed Pharmaceuticals stock for Q4 2023, up 101% quarter-over-quarter.
  • 9 funds opened new Oramed Pharmaceuticals positions in Q4 2023 and 9 closed out, a net change of 0 holders.
  • The largest Oramed Pharmaceuticals buyer in Q4 2023 was Murchinson, an estimated $2.24M added.
  • The largest Oramed Pharmaceuticals seller in Q4 2023 was Goldman Sachs, an estimated $401K sold.

Based on aggregated 13F filings for Q4 2023.